SCIENTIFIC PUBLICATIONS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
International Conference in Malignant Lymphoma (ICML) 2019 – STRO-001 Poster
Preliminary results of a Phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies. Please Click the Link, International Conference in Malignant Lymphoma 2019 poster to...
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., June 18, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
European Hematology Association Congress (EHA) 2019 – STRO-001 Poster
Preliminary results of a Phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies. Please Click the Link, EHA_2019 STRO-001 poster to enlarge.
European Hematology Association (EHA) 2019 – STRO-001 Abstract
Preliminary Results Of A Phase 1 Dose Escalation Study Of The First-In-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, In Patients With Advanced B-Cell Malignancies. Abstract PS1071 BackgroundCD74 is expressed on B cells throughout differentiation and is an...
Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress
SOUTH SAN FRANCISCO, Calif., May 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming European Hematology Association (EHA) Congress being held June 13-16, 2019, in Amsterdam. The abstract summarizes preliminary...
American Association for Cancer Research (AACR) 2019 – STRO-002 Abstract 3897
American Association for Cancer Research (AACR) 2019 Abstract 3897: Stability and safety evaluation of STRO-002, a site-specific anti-folate receptor alpha antibody-drug conjugate for the potential treatment of ovarian and endometrial cancers.
American Association for Cancer Research (AACR) 2019 – STRO-002 Poster
American Association for Cancer Research (AACR) 2019 A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-002, An Anti-Folate Alpha (FolRα) Antibody Drug Conjugate, In Patients With Advanced Epithelial Ovarian Cancer (Including...
American Association for Cancer Research (AACR) 2019 – STRO-001 Poster
A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-001, An Anti-CD74 Antibody Drug Conjugate, In Patients With Advanced B-Cell Malignancies, NCT03424603
Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central...